Effect of GOCOVRI (Amantadine, Extended Release Capsules) on Gait in Parkinson's Disease
Status:
Recruiting
Trial end date:
2021-09-30
Target enrollment:
Participant gender:
Summary
The purpose of the study is to learn about the effect of GOCOVRI (Amantadine extended
release) on activity levels and measures of gait and balance quality in people with
Parkinson's disease (PD) and levodopa induced dyskinesia (LID) during daily activities using
body-worn sensors.